Elevated levels of Foxo1 have long been implicated in the pathogenesis of metabolic disorders and drug resistance in certain types of cancers, and small molecule inhibitors of Foxo1 have been proposed as a form of pharmacologic treatment (Goto et al., 2008; Pandey et al., 2016). The gene discussed is FOXO1; the disease is Other metabolic disease.